Home Therapeutic Areas Cardio-Metabolic
Product information is intended for healthcare professionals. Please refer to the approved prescribing information for full details of indications, dosage and safety.
Vixvert® Indication: Prevention and treatment of venous thromboembolic disorders, including DVT and pulmonary embolism (PE), and prevention of VTE following hip or knee replacement surgery. Strengths: 10 mg, 15 mg, 20 mg Dosage Form: Film-Coated Tablets Active Ingredient: Rivaroxaban
Ticagrelor SPC® Indication: Used in combination with acetylsalicylic acid (ASA) to reduce the risk of cardiovascular events in adults with acute coronary syndrome (ACS), including heart attack or unstable angina. Strength: 90 mg Dosage Form: Film-Coated Tablets Active Ingredient: Ticagrelor
Fondaparinux SPC® (Fondaparinux Injection 5 mg/mL) Indication: Prevention of blood clots after hip, knee, or abdominal surgery, and treatment of DVT and pulmonary embolism (PE) in combination with warfarin. Strength: 5 mg/mL Dosage Form: Injection Active Ingredient: Fondaparinux
Pixar® (Apixaban Film-Coated Tablets) Indication: Prevention and treatment of thromboembolic disorders, including DVT, pulmonary embolism (PE), and stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Strengths: 2.5 mg, 5 mg Dosage Form: Film-Coated Tablets Active Ingredient: Apixaban
Saventi® Indication: Treatment of chronic heart failure in adults to improve cardiovascular outcomes. Strengths: 50 mg, 100 mg, 200 mg Dosage Form: Film-Coated Tablets Active Ingredient: Sacubitril/Valsartan
Monzeva® Indication: Treatment of type 2 diabetes mellitus in adults, as monotherapy or in combination with other antidiabetic medications. Strengths: 10 mg, 25 mg Dosage Form: Film-Coated Tablets Active Ingredient: Empagliflozin
Juleen® Indication: Treatment of type 2 diabetes mellitus in adults to improve glycemic control, as monotherapy or in combination with other antidiabetic medications. Strengths: 25 mg, 50 mg, 100 mg Dosage Form: Film-Coated Tablets Active Ingredient: Sitagliptin
Daglozin® Indication: Treatment of type 2 diabetes mellitus in adults and children ≥10 years, as monotherapy or in combination with other antidiabetic medications. Strengths: 5 mg, 10 mg Dosage Form: Film-Coated Tablets Active Ingredient: Dapagliflozin
